Are pre-miR-146a and PTTG1 associated with papillary thyroid cancer? by M. Marino et al.
E
n
d
o
cr
in
e
C
o
n
n
e
ct
io
n
s
Research
Open Access
M Marino et al. PTC, pre-miR-146a, and PTTG1 1–8 2 :178Are pre-miR-146a and PTTG1
associated with papillary
thyroid cancer?Marco Marino1,2, Valentina Cirello3,4, Valentina Gnarini1, Carla Colombo3,4,
Elisa Pignatti1,2, Livio Casarini1,2, Chiara Diazzi1, Vincenzo Rochira1,5, Katia Cioni5,
Bruno Madeo5, Cesare Carani1,5, Manuela Simoni1,2,5 and Laura Fugazzola3,4
1Unit and Chair of Endocrinology and Metabolism, NOCSAE, Department of Biomedical, Metabolic and
Neural Sciences, University of Modena and Reggio Emilia, Via Pietro Giardini 1355, 41126 Modena, Italy
2Center for Genomic Research, University of Modena and Reggio Emilia, Modena, Italy
3Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy
4Endocrine Unit, Fondazione IRCCS Ca’ Granda Milan, Milan, Italy
5Azienda USL of Modena, Modena, Italyhttp://www.endocrineconnections.org
DOI: 10.1530/EC-13-0066
 2013 The authors
Published by Bioscientifica Ltd
This work is l
Attribution 3Correspondence
should be addressed
to M Simoni
Email
manuela.simoni@unimore.itAbstractPapillary thyroid carcinoma (PTC) is the most common endocrine malignancy, with a steadily
increasing incidence in the last few decades worldwide. The predisposition to developing this
carcinoma by the heterozygous state of rs2910164 within the precursor of the miR-146a has
been reported, but recently not confirmed. Interestingly, on the same chromosome, almost
50 kb separate the pre-miR-146a from the pituitary tumor-transforming gene 1 (PTTG1), a
proto-oncogene involved in several tumors, including thyroid cancers. In this study, we
analyzed, using a case–control design, the genetic association between PTC and the genomic
region encompassing pre-miR-146a rs2910164 and PTTG1 rs1862391 and rs2910202. We
enrolled 307 affected patients and 206 healthy controls. The possible presence of thyroid
nodules in controls was excluded by ultrasonography. All the cases were submitted to single-
nucleotide polymorphism (SNP) genotyping of pre-miR-146a and PTTG1, and risk association
analyses were carried out. The genotypic and allelic frequencies of pre-miR-146a rs2910164
were not statistically different in the patients and controls, and this SNP was not in linkage
disequilibrium with the investigated PTTG1 SNPs. Consistently, meta-analyses, the first
including all the affected cases published to date, did not confirm the previously reported
association of the heterozygous CG genotype with PTC. The PTTG1 SNPs exhibited the same
allelic frequency in the patients and controls and were not associated with the disease.
In conclusion, in a well-selected Italian population, neither pre-miR-146a rs2910164 nor PTTG1
rs1862391 and rs2910202 were found to be associated with the risk of developing PTC.Key Words
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.0 UEndocrine Connections
(2013) 2, 178–185IntroductionThyroid cancers can be well-differentiated, as papillary
and follicular subtypes, or poorly differentiated and
anaplastic carcinomas. Papillary thyroid carcinoma (PTC)
represents up to 80% of all the thyroid cancer cases.Various molecular alterations have been reported to be
associated with PTC, including BRAF (40–45%) and RAS
(10–20%) point mutations and RET (10–20%) or TRK
(NTRK1) (!5%) rearrangements, all involved in thesed under a Creative Commons
nported License.
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the literature has a large amount of information on these
alterations, there are a few cases of PTC that are not
associated with the mutations mentioned above. To fill
this gap, the scientific community is still actively searching
for new diagnostic and prognostic molecular markers of
PTC. In the last 8 years, studies on PTC have been focused
on microRNAs (miRNAs), a class of endogenous, small
noncoding RNA molecules that function as negative
regulators of the expression of protein-encoding genes,
involved in many cellular processes such as development,
apoptosis, and proliferation (3, 4). The first evidence for a
potential role for several miRNAs in PTC was the different
expression of some of these miRNAs in tumor tissue,
compared with unaffected tissue of the thyroid gland (4).
In particular, two studies have shown the association
between pre-miR-146a rs2910164 and PTC, evaluating the
impact of this single-nucleotide polymorphism (SNP) on
the regulation of target mRNAs (5, 6). As a conclusion,
these studies reported an association between the pre-miR-
146a CG genomic variant (rs2910164) and the predisposi-
tion to developing PTC. However, further case–control
studies, including Caucasian and Asian populations, have
been unable to confirm this association (7, 8). Therefore,
the involvement of the genomic variant pre-miR-146a
rs2910164 in thyroid cancers remains unclear.
Interestingly, on the same chromosome 5, w50 kb
separate pre-miR-146a (OMIM*610566) from the pituitary
tumor-transforming gene 1 (PTTG1) (OMIM*604147),
reported to be overexpressed in thyroid carcinomas
(9, 10, 11). PTTG1, encoding a securin homolog, is
involved in the physiological control of mitosis, DNA
repair, gene regulation, and fetal development (12, 13).
When experimentally mutated, this gene has been shown
to promote the proliferation of cancer, to repress the
reparation of double-stranded DNA breaks, and to interact
with different factors, possibly driving the progression of
the disease (13). It has recently been shown that the
genomic region on chromosome 5, encompassing pre-miR-
146a and PTTG1, is associated with systemic lupus
erythematosus (SLE) (12, 14) and cancers (15, 16, 17),
including papillary thyroid tumor (5, 6, 7, 8, 10). The aim
of the present study was to analyze this region and its
association with PTC in a well-selected case–control
population of the Northern area of Italy, adopting, as
genetic markers, the rs2910164 SNP of pre-miR-146a and,
for the first time, the rs1862391 and rs2910201 SNPs of
PTTG1. The latter gene was selected both for its
involvement in cancers and for its genomic proximity to
pre-miR-146a, making it a possible ‘true’ candidate for thehttp://www.endocrineconnections.org
DOI: 10.1530/EC-13-0066
 2013 The authors
Published by Bioscientifica Ltdgenomic association with PTC previously inconsistently
found with pre-miR-146a.
In addition, we carried out meta-analyses on the data
reported in the literature (6, 7, 8), including our data,
considering Caucasian and Asian populations.Subjects and methods
Subjects
Using a case–control study design, 307 patients (83 males
and 224 females) diagnosed as having PTC and 206
healthy control subjects (75 males and 131 females), all
of Caucasian origin and Italian ethnicity, were enrolled.
The majority of cases (192/307) were recruited at the
Endocrine Unit of the University of Modena and Reggio
Emilia, while 115 patients were recruited at the Endocrine
Unit of the University of Milan. Tumors were classified
according to the thyroid malignancy World Health
Organization classification and staged according to the
sixth edition of TNM staging (18). Controls, 137/206 from
Modena and 69/206 from Milan, were selected among the
volunteers. Importantly, to be enrolled, controls had to
have a normal thyroid function and a normal ultrasound
scan, excluding autoimmune or nodular diseases. The
total number of 307 patients and 206 controls satisfied the
criteria of the power analysis, requiring a minimum
sample size of 164 patients. Written informed consent
was obtained from all the participants, who donated a
blood sample for association studies on thyroid cancers.
The study protocol was approved by the Local Ethics
Committee (file no. 122/08).Criteria for the selection of SNPs
We selected the rs2910164 SNP of the pre-miR-146a gene
because of its direct association with PTC, as reported in
the literature (5, 6, 7, 8).
For PTTG1, four different SNPs have been considered
in previous studies. Brendle et al. (19) investigated
rs1862391, rs1862392, and rs2961952 in breast cancer,
whereas Lo¨fgren et al. (12) and Yang et al. (20) described
rs2431697 associated with SLE and psoriasis. Based on this
information, we decided to analyze the genomic region
corresponding to PTTG1, including these four SNPs, but
using other, more informative genetic markers following
the guidelines of Pettersson et al. (21) for genetic
association studies. The online database ‘HapMap’
(http://hapmap.ncbi.nlm.nih.gov) contains 32 annotated
SNPs in the region of over 10 kb encompassing the wholeThis work is licensed under a Creative Commons
Attribution 3.0 Unported License.
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4.2 (Harvard University and Massachusetts Institute of
Technology, USA) to verify those falling within a block of
linkage disequilibrium (LD), using the LD parameters D 0
and r2 (21). By considering the minor allele frequency
(MAF) available in HapMap and the degree of allelic
correlation between LD blocks, two SNPs were identified as
the best haplotype marker candidates (D 0Z1 and r2Z1;
Fig. 1A): rs1862391 (A/C) and rs2910202 (C/T). These SNPs
exhibit the same MAF, corresponding to the highest MAF
among all the SNPs belonging to the PTTG1 LD block (29%
for Utah residents with Northern and Western European
ancestry from the CEPH collection, CEU; Fig. 1A). Of
these, rs1862391 had been studied previously in breast
cancer cases (19). Our analysis revealed several criteria of
inadequacy for the other three SNPs studied previously in
the literature, such as low probability of LD and differentFigure 1
(A) Haploview window showing the PTTG1 gene and its LD block,
containing the two selected SNPs, rs1862391 and rs2910202. The
percentage of LD is shown in each diamond. Black diamonds without
a number correspond to 100% of LD (D 0Z1.0, r2Z1). (B) Results of the
http://www.endocrineconnections.org
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Published by Bioscientifica LtdMAF (between rs1862391 and rs1862392) and the
exclusion from LD blocks (rs2961952 and rs2431697).
Particularly, the rs2431697 SNP neither belongs to PTTG1
nor falls within the PTTG1 LD block; furthermore, the
distance between this SNP and the gene is over 23 kb. The
rs1862391 SNP is located at about 500 bp upstream
the first exon, inside the promoter region, while the
rs2910202 SNP lies about 400 bp downstream exon 3
(between exons 3 and 4). A distance of 2.2 kb separates the
two selected PTTG1 SNPs (Fig. 1A), while a distance of
63.9 kb separates the rs1862391 SNP of PTTG1 from the
rs2910164 SNP of pre-miR-146a (Fig. 1B).Genomic DNA analysis
DNA was extracted from the whole peripheral blood of all
the patients and controls, using the Nucleon BACC2 Kitanalysis of LD between PTTG1 rs1862391 and pre-miR-146a rs2910164
showing a distance of 63.9 kb between the two SNPs and a very low
percentage of LD, 34% (D 0Z0.343, r2Z0.014).
This work is licensed under a Creative Commons
Attribution 3.0 Unported License.
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genotype the pre-miR-146a rs2910164 SNP, at least 100 ng
of DNA were PCR-amplified using specific intronic primers
in a One-Advanced Thermocycler (Euroclone S.p.A., Life
Sciences Division, Siziano, Italy), according to the
following protocol: 98 8C for 5 min followed by 35 cycles
of 98 8C for 1 min, 58 8C for 1 min, and 72 8C for 2 min
with a final step of 72 8C for 10 min. The PCR products
were directly sequenced after the removal of the unin-
corporated dNTPs and primers using ExoSAP-IT (USB
Products Affymetrix, Inc., Cleveland, OH, USA). An
aliquot of 3–10 ng/100 bp of purified DNA and 3.2 pmol
of either the forward or reverse primer was used in
standard cycle sequencing reactions with ABI PRISM
BigDye Terminators and run on the ABI PRISM 310
Genetic Analyzer (PE Applied Biosystems). The cycle
sequencing conditions consisted of 25 cycles of 96 8C for
30 s, 50 8C for 15 s, and 60 8C for 4 min. One sequence read
from each direction across the entire coding region and
including intron–exon boundaries was obtained for each
sample. All the primers used for PCR and sequences are
listed in Supplementary Table 1, see section on supple-
mentary data given at the end of this article. Electro-
pherograms were analyzed using the Chromas Software
(http://technelysium.com.au).
Genotyping for the two PTTG1 SNPs, rs1862391 and
rs2910202, was carried out using the High Resolution
Melting (HRM) technology on a CFX96 Real-time PCR
detection system (Bio-Rad Laboratories). The Beacon
Designer 7.91 Software (Bio-Rad) was used to design and
test, in silico, all the HRM primers (Supplementary Table 1).
To conduct HRM assays, 20 ng of genomic DNA were
amplified in a final volume of 15 ml, containing 1! SsoFast
Eva Green Supermix (Bio-Rad) and 0.5 mmol/l of each
primer. The conditions of qPCR were as follows: 98 8C for
2 min followed by 39 cycles of 3 s at 98 8C and 5 s at
58.2 8C (for rs1862391) or 58.2 8C (for rs2910202). After
the amplification step, the PCR products were denatured
at 98 8C for 30 s and slowly renatured at 65 8C for 90 s.
A high-resolution melt was immediately carried out with a
progressive denaturation step from 67 to 80 8C (for
rs1862391) or from 66 to 84 8C (for rs2910202), by
increasing the temperature by 0.2 8C every 10 s. All the
HRM raw data (preliminary melting curves) were analyzed
using the specific software CFX Manager (Bio-Rad) and
Precision Melt Analysis (Bio-Rad). Uncertain results were
verified through Sanger sequencing using the 4-capillary
ABI Prism 3130 Genetic Analyzer (Applied Biosystems).
The FastPCR 6.0 Software (Primer Digital Ltd., Helsinki,
Finland) (22) was used to design the PCR and sequencehttp://www.endocrineconnections.org
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Published by Bioscientifica Ltdprimers for the two PTTG1 SNPs (Supplementary Table 1).
Electropherograms were analyzed using the Sequencing
Analysis 5.3.1 Software (Applied Biosystems). The
accuracy of pre-miR-146a rs2910164 genotyping was
assessed by repeating the genotyping analysis for 40
randomly chosen samples. The accuracy of PTTG1 SNP
genotyping was assessed by the perfect LD between the
two SNPs, as expected in CEU. The success rate of
genotyping was 100%.Statistical analyses
To assess the minimum sample size for the present study to
be valid, a power analysis was carried out using the GPower
3.1.6 Software (Dusseldorf, Germany) (effect size wZ0.30;
aZ0.05; powerZ0.97), following the programmer’s
instructions (23). The c2 test was used to assess the
deviation from the Hardy–Weinberg equilibrium (HWE)
in the control group and to analyze the differences in
genotype distribution and allelic frequencies between the
patients and controls. The odds ratio (OR) and its 95% CI
were used to assess the strength of the association between
the analyzed polymorphisms and the disease. In meta-
analyses, heterogeneity between all the analyses was
determined by I2, and data with high heterogeneity (I2O
50%) were processed using a random-effects model or a
fixed-effects model (24). All the statistical analyses were
carried out using the GraphPad Prism 5 Software (www.
graphpad.com), and the Review Manager 5.2 Software
(Copenhagen, Denmark) was used for the meta-analyses.
P value!0.05 was considered to be statistically significant.Results
The genotype results did not deviate from the HWE
compared with those of the HapMap CEU population
(PZ0.3517 for pre-miR-146a and PZ0.4084 for PTTG1). In
addition, the statistical analyses revealed no differences in
genotype distribution between the patients enrolled in
Modena and those enrolled in Milan (PZ0.3650 for
pre-miR-146a and PZ0.3684 for PTTG1). Similarly, no
differences were evident between controls recruited at the
two sites (PZ0.9193 for pre-miR-146a and PZ0.8492 for
PTTG1); thus, all the data of patients and controls were
assessed together.
No significant differences in genotype distribution
and allelic frequencies of pre-miR-146a rs2910164 were
found between the patients and controls (Table 1). The OR
analysis did not reveal any significant risk association
between the CC or GG genotype and PTC (Table 1). TheThis work is licensed under a Creative Commons
Attribution 3.0 Unported License.
Table 1 Genotype distribution and allelic frequencies of pre-miR-146a rs2910164 in PTC cases and controls.
rs2910164 PTC cases (n (%)) Controls (n (%)) c2 Odds ratio (%) 95% CI P value
Total n 307 206
Genotype PZ0.2299
GG 180 (58.6) 105 (51) 1.363 (GG vs CGCCC) 0.9556–1.945 0.0869
CG 105 (34.2) 84 (40.8) 0.755 (CG vs GGCCC) 0.5243–1.087 0.1302
CC 22 (7.2) 17 (8.2) 0.8582 (CC vs GGCCG) 0.4439–1.659 0.649
Allele PZ0.1175
C 149 (24.3) 118 (28.6) Reference
G 465 (75.7) 294 (71.4) 1.253 (G vs C) 0.9445–1.661 0.1175
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Research M Marino et al. PTC, pre-miR-146a, and PTTG1 5–8 2 :182previously described association of the CG genotype with
PTC (5, 6) was not confirmed (Table 1).
All the meta-analyses were carried out by combining
the results of the present study with the data of
independent association studies from the literature
(6, 7, 8). The meta-analyses did not detect an association
either between pre-miR-146a rs2910164 alleles and PTC
(Fig. 2A) or between genotypes and PTC (Fig. 2B, C and D).(6) 319
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Figure 2
Results of the meta-analyses for the association risk between pre-miR-146a
rs2910164 and PTC. All the meta-analyses included the Caucasian and Asian
ethnic subgroups. All the considered studies and all the results of the meta-
analyses are represented by the forest plot. The size of the squares indicates
the weight of each individual study. The diamond on the top corresponds
to the result of the meta-analyses, applied to the Caucasian subgroup,
Asian subgroup, or both subgroups. M–H, Mantel–Haenszel method.
(A) The plot, showing an OR of 1.0228, presents the association risk
between the alleles (C vs G) of pre-miR-146a rs2910164 and papillary cancer
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Published by Bioscientifica LtdFor PTTG1, the perfect LD between the rs1862391 and
rs2910202 SNPs was confirmed. The genotypic and allelic
frequencies of the patients and controls were not different
(Table 2). No risk associations were found between the two
PTTG1 SNPs and PTC (Table 2). The degree of LD between
pre-miR-146a rs2910164 and the chosen PTTG1 SNPs was
low (34%, Fig. 1B).(6) 16
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and indicates an association that is not significant. (B) The plot, showing an
OR of 0.9653, presents the association risk between the GG genotype of
pre-miR-146a rs2910164 and papillary cancer and indicates an association
that is not significant. (C) The plot, showing an OR of 1.0457, presents
the association risk between the CG genotype of pre-miR-146a rs2910164
and papillary cancer and indicates an association that is not significant.
(D) The plot, showing an OR of 0.8426, presents the association risk
between the CC genotype of pre-miR-146a rs2910164 and papillary
cancer and indicates an association that is not significant.
This work is licensed under a Creative Commons
Attribution 3.0 Unported License.
Table 2 Genotype distribution and allelic frequencies of PTTG1 rs1862391 in PTC cases and controls.
rs1862391 PTC cases (n (%)) Controls (n (%)) c2 Odds ratio 95% CI P value
Total n 307 206
Genotype PZ0.9798
AA 185 (60.7) 123 (59.7) 1.023 (AA vs ACCCC) 0.7137–1.467 0.9005
AC 101 (32.6) 68 (33) 0.995 (AC vs AACCC) 0.6834–1.449 0.9791
CC 21 (6.7) 15 (7.3) 0.935 (CC vs AACAC) 0.4701–1.860 0.8479
Allele PZ0.8541
C 143 (23.3) 98 (23.8) Reference
A 471 (76.7) 314 (76.2) 1.028 (A vs C) 0.7660–1.379 0.8541
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SNPs, often were not informative, we extended the
analysis by assessing the risk associated with the nine
possible diplotypes, arising from the combination of all
genotypes of the two SNPs, pre-miR-146a rs2910164 and
PTTG1 rs1862391 (Table 3). This analysis did not reveal
any specific diplotype to be associated with PTC (Table 3).Discussion
In recent years, scientific research has been increasingly
orientated to understanding the physiological role and
implication of miRNAs in several cancers. Conflicting
results exist about the role of pre-miR-146a rs2910164 in
thyroid cancers. Indeed, although a significant association
between the heterozygous CG genotype of rs2910164 and
PTC has been reported, investigating three different
Caucasian populations (from Finland, Poland, and USA)
(6), these data have not been confirmed in two series of
Caucasian (7) and Asian (8) origins. In particular, by
comparing patients with benign thyroid tumors with
patients with PTC, Wei et al. (8) reported that the GG
genotype rather than the CG genotype represented a
significant risk factor associated with malignant transfor-
mation in a Chinese Han population. In the present study,
neither the pre-miR-146a rs2910164 SNP nor the PTTG1Table 3 Odds ratios (ORs) for the risk of developing PTC based
rs1862391 (PTTG1).
Diplotype rs2910164 rs1862391 PTC cases (n (%)) Controls
Total n 307 206
1 GG AA 101 (32.9) 56 (27
2 GG AC 65 (21.2) 40 (19
3 GG CC 14 (4.6) 9 (4.
4 CG AA 68 (22.1) 55 (26
5 CG AC 31 (10.1) 24 (11
6 CG CC 6 (2) 5 (2.
7 CC AA 16 (5.2) 12 (5.
8 CC AC 5 (1.6) 4 (1.
9 CC CC 1 (0.3) 1 (0.
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Published by Bioscientifica Ltdrs1862391 and rs2910201 SNPs were found to be associ-
ated with PTC. The differences between the results of the
present study and those of the study carried out by
Jazdzewski et al. (6) could be due to the different number of
patients and controls enrolled, which was lower in the
present study. Nevertheless, discordant results have also
been obtained in the three larger series published by
Jazdzewski et al. (6), Jones et al. (7), and Wei et al. (8),
including 608, 748, and 753 PTC cases respectively.
Another possibility could lie in the selection of controls,
which has previously been carried out based on only
anamnestic criteria. By contrast, in the present study, the
control subjects were screened and selected on the basis of
a normal thyroid ultrasound scan. Owing to the high
prevalence of nodular diseases worldwide, and in particu-
lar in regions such as Italy, with a mild iodine deficiency,
several subjects were excluded due to the incidental
demonstration of nodules of any dimension in the
absence of clinical signs and symptoms. In particular, we
have recently shown that thyroid abnormalities such as
nodular goiter and thyroiditis are present in 50.3% of
asymptomatic subjects from in Italy (25). Moreover,
differentiated thyroid cancer was found in 1% of the
screened, asymptomatic subjects and in 2% of those
affected by nodular goiter (25). Since previous association
studies did not select the control group on the basis of aon genotype combinations of rs2910164 (pre-miR-146a) and
(n (%)) OR 95% CI P value
.2) 1.313 (diplotype 1 vs all) 0.8905–1.937 0.2009
.4) 1.115 (diplotype 2 vs all) 0.7174–1.732 0.6566
4) 1.046 (diplotype 3 vs all) 0.4440–2.464 1.0000
.7) 0.7811 (diplotype 4 vs all) 0.5185–1.177 0.2472
.7) 0.8518 (diplotype 5 vs all) 0.4841–1.499 0.6806
4) 0.8013 (diplotype 6 vs all) 0.2412–2.662 0.9589
8) 0.8889 (diplotype 7 vs all) 0.4114–1.921 0.9190
9) 0.8361 (diplotype 8 vs all) 0.2218–3.152 0.9376
5) 0.6699 (diplotype 9 vs all) 0.04164–10.78 0.6613
This work is licensed under a Creative Commons
Attribution 3.0 Unported License.
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Research M Marino et al. PTC, pre-miR-146a, and PTTG1 7–8 2 :184normal thyroid ultrasound scan (6, 7, 8), it is tempting to
speculate that differences in the selection criteria might
explain at least in part the discrepancies of the literature.
In such cases, meta-analyses may be helpful. In several
published studies, meta-analyses have been carried out to
clarify the actual association among polymorphic variants
and cancers or other diseases (24, 26, 27). Recently, this
kind of analyses has been carried out for evaluating the
association between the pre-miR-146a rs2910164 SNP
and over 15 different types of cancers (26, 28, 29, 30, 31,
32, 33). In the present study, meta-analyses focused only
on the possible association between pre-miR-146a
rs2910164 and PTC have been carried out for the first
time. Caucasian and Asian ethnic subgroups were
considered, separately or together, and the risk association
according to the different alleles and genotypes (Fig. 2A, B,
C and D) was analyzed. Our meta-analyses included all the
studies based on rs2910164 in PTC carried out so far. To
the best of our knowledge, no genome-wide association
studies on PTC have focused on rs2910164, rs1862391, or
rs2910202 so far. Our meta-analyses, including a total of
2416 patients and 7925 controls, did not confirm the
association of pre-miR-146a rs2910164 with PTC using any
of the models analyzed (dominant or recessive). Therefore,
we must conclude that, according to the current knowl-
edge, the genotypes of pre-miR-146a, as assessed in
peripheral blood leukocytes, are not associated with PTC
(Fig. 2B, C and D).
Given the proximity of PTTG1 to pre-miR-146a and its
postulated role in cancers, we extended our analyses to this
gene. We reasoned that PTTG1 could be associated with
PTC, since a previous study had reported the association of
the rs2431697 SNP, located in the intergenic region
dividing the PTTG1 and pre-miR-146a genes, with SLE
(12). Moreover, several studies have shown the involve-
ment of PTTG1 in the onset and/or progression of different
types of tumors (10, 11, 13, 15, 16, 17), including thyroid
cancers (10). The postulated role of securin, the protein
encoded by PTTG1, in thyroid tumorigenesis and in the
development of hyperplastic lesions could be due to its
overexpression during metaphase–anaphase transition
(10), which could generate aneuploidy (10, 13). Taking
all these data into consideration, we decided to explore the
association of PTTG1with PTC, using, for the first time, the
rs1862391 A/C and rs2910201 C/T SNPs as genetic markers.
The PTTG1 SNPs (rs1862391 and rs2910202), in perfect LD,
exhibited the same allelic frequency in patients and
controls and were not associated with PTC, probably
excluding a possible role of this gene in thyroid
tumorigenesis.http://www.endocrineconnections.org
DOI: 10.1530/EC-13-0066
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Published by Bioscientifica LtdIn conclusion, the present case–control study, in a
well-selected population of the Northern area of Italy, and
the meta-analyses, combining the results of all the
association studies carried out so far, demonstrate that
pre-miR-146a rs2910164 is not associated with PTC. In
particular, no genotype was found to be associated with an
increased risk of developing PTC, including the previously
suggested heterozygous CG genotype. Extending the
genetic analysis to the contiguous genomic region, we
showed that PTTG1 was not associated with PTC. In the
light of these data, the genomic region encompassing
pre-miR-146a and PTTG1 is probably not associated with
the predisposition to developing PTC. The occurrence of
PTTG1 gene mutations in PTC patients and the role of
somatic mutations of both the investigated genes remain
to be explored.Supplementary data
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